047 COMBINATION OF TENOFOVIR/EMTRICITABINE WITH PROTEASE INHIBITOR - BASED REGIMEN INDUCED ACUTE KIDNEY INJURY REQUIRING HAEMODIALYSIS: A CASE REPORT

Bibliographic Details
Main Authors:	C.M. Ang, M. Ramadhan, MD, H. Norra, A. Rafidah
Format:	Article
Language:	English
Published:	Elsevier 2017-08-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024917302589

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
by: Squillace N, et al.
Published: (2018-10-01)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
by: Eric H. Decloedt, et al.
Published: (2021-04-01)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity
by: Ortu F, et al.
Published: (2010-02-01)

Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
by: Rashmee Patil, et al.
Published: (2015-01-01)

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
by: Xinhui Chen, et al.
Published: (2016-01-01)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
by: Gregory D Huhn, et al.
Published: (2020-01-01)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
by: Lucia Taramasso, et al.
Published: (2019-01-01)

Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
by: Sara Iannuzzi, et al.
Published: (2021-07-01)

Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
by: Bruno Emond, et al.
Published: (2021-06-01)

Evaluation of urinary excretion of dolutegravir or emtricitabine/tenofovir/elvitegravir/cobicistat antiretroviral-based regimens using plasma and urine trough concentration
by: Jérémy Lourenco, et al.
Published: (2018-05-01)

Rates of Switching First-Line Antiretroviral Regimen Tenofovir-Emtricitabine-Efavirenz combination in a Primary Care Service in South Africa
by: Huang, David
Published: (2020)

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.
by: J Gerardo García-Lerma, et al.
Published: (2008-02-01)

Simple Spectrophotometric Methods for Determination of Tenofovir Fumarate and Emtricitabine in Bulk Powder and in Tablets
by: Mohammad H. AbdelHay, et al.
Published: (2013-01-01)

Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC
by: Arun Ramaswamy, et al.
Published: (2018-02-01)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
by: Wissam K. Kabbara, et al.
Published: (2015-09-01)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
by: Juday T, et al.
Published: (2013-09-01)

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention
by: Meredith R. Clark, et al.
Published: (2014-12-01)

Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis
by: Loraine Van Slyke FNP-C, et al.
Published: (2018-03-01)

Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion
by: Shui-Shan Lee, et al.
Published: (2020-05-01)

New simple spectrophotometric method for determination of the antiviral mixture of emtricitabine and tenofovir disoproxil fumarate
by: Heba K. Ashour, et al.
Published: (2017-05-01)

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
by: Prinapori R, et al.
Published: (2015-08-01)

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
by: Mohammed Lamorde, et al.
Published: (2012-01-01)

Gradient high performance liquid chromatographic method for the simultaneous analysis of efavirenz, emtricitabine and tenofovir
by: Koekemoer, Sonya Mariana
Published: (2016)

Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial
by: Andrea R. Thurman, MD, et al.
Published: (2021-06-01)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
by: Bernardini C, et al.
Published: (2013-06-01)

Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives
by: James AM, et al.
Published: (2013-08-01)

Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance
by: Yu-Yu Hsiao, et al.
Published: (2021-08-01)

Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT)
by: Arasteh K, et al.
Published: (2009-05-01)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
by: Josep M Llibre, et al.
Published: (2015-01-01)

Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications
by: Rui Ma, et al.
Published: (2020-12-01)

A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
by: Collins C. Iwuji, et al.
Published: (2020-07-01)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and HBV co-infection
by: Y.-S. Huang, et al.
Published: (2019-07-01)

RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form
by: Tej Kumar Kokkirala, et al.
Published: (2019-12-01)

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
by: Allison Martin, et al.
Published: (2011-01-01)

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2012-01-01)

Cellular mechanisms underlying the cardiovascular toxicity of the highly active anti-retroviral therapy Atripla : efavirenz, emtricitabine and tenofovir
by: Faltz, Mary
Published: (2013)

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar
by: Hussam Al Soub, et al.
Published: (2020-01-01)

Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.
by: Nicholas T Funderburg, et al.
Published: (2013-01-01)

047 COMBINATION OF TENOFOVIR/EMTRICITABINE WITH PROTEASE INHIBITOR - BASED REGIMEN INDUCED ACUTE KIDNEY INJURY REQUIRING HAEMODIALYSIS: A CASE REPORT

Similar Items

Similar Items